Pharmacy and public health: collaborative models that work

Pharmacists are among the most frequently visited health professionals in Australia, with the community pharmacy network reaching into every suburb and most country towns. That reach places pharmacy at the front line of public health, not just at the dispensing bench. When the goal of public health is keeping populations well rather than only treating those who fall ill, the pharmacist's role shifts from transactional to relational. Trust built over years of quick conversations at the counter becomes a clinical asset.

Across Australia, models that pair pharmacy with public health agencies are quietly reshaping what preventive care looks like. From vaccination drives in regional Western Australia to naloxone provision in inner Sydney, the work is collaborative by necessity. State and federal health bodies, primary health networks, Aboriginal community controlled health organisations, and local councils are all sitting at the same table as pharmacists more often than they did a decade ago.

This shift matters because Australia's health system carries a familiar set of pressures. An ageing population, rising rates of mental ill-health, persistent gaps in regional and remote care, and the long tail of COVID-19 have stretched every part of the sector. Pharmacy cannot solve these problems alone, but the evidence for what happens when it works alongside public health partners is now substantial enough to inform how the next Community Pharmacy Agreement is designed.

Pharmacists as frontline public health practitioners

The Australian public has long treated the local chemist as a first point of contact for minor ailments, and that habit has quietly turned pharmacists into de facto public health workers. In the last decade the scope of practice has expanded under successive Community Pharmacy Agreements, with pharmacists now able to administer a growing list of vaccines, deliver structured diabetes screening, and offer health checks that previously required a GP appointment. For a country the size of Australia, where distance to a general practice can be measured in hundreds of kilometres, that expanded scope is not a luxury.

Pharmacists are also helping to address the workforce gaps that have been documented in rural and remote communities for decades. Programs like the Rural Pharmacy Network and the Pharmacy Workforce Incentive Program have tried to anchor pharmacists in towns that would otherwise rely on fly-in locums. Where these schemes have worked, the result is a clinician who knows the local community by name, knows which families are struggling with medication adherence, and can flag concerns to a GP or public health unit before a small issue becomes a hospital admission.

The training pipeline is changing to match this broader role. The Australian Pharmacy Council's accreditation standards now expect graduates to demonstrate competence in population health, health promotion, and cultural safety, particularly in relation to Aboriginal and Torres Strait Islander health. That expectation shows up in pharmacy curricula at universities in Brisbane, Melbourne, Sydney, and Perth, and it is slowly changing what a pharmacist consultation feels like at the counter.

Vaccination, screening, and preventive care in the community pharmacy setting

Immunisation is the clearest example of pharmacy-public health collaboration paying off. The expansion of pharmacist-administered vaccines across all states and territories, including travel vaccines and adult catch-up schedules, took pressure off general practice and lifted overall coverage. The Pharmacy Guild of Australia regularly reports that community pharmacies now deliver a meaningful share of the nation's flu and COVID-19 jabs, and that share is highest in outer metropolitan and regional areas where GP access is patchier.

Screening programs have followed a similar path. The Heart Foundation's collaboration with pharmacies on blood pressure checks, the National Bowel Cancer Screening Program's pharmacy-endorsed promotion, and cholesterol point-of-care testing pilots in Tasmania have all drawn on the convenience of the pharmacy visit. The patient does not need an appointment, the test takes minutes, and the result is interpreted on the spot by a clinician who can refer onward. That model of opportunistic screening fits neatly with how many Australians already use their pharmacy.

Medication management services such as MedsCheck, Diabetes MedsCheck, and Home Medicines Reviews sit alongside these preventive activities and quietly reduce harm. A Home Medicines Review, for instance, often uncovers discrepancies that a GP review in a ten-minute appointment would miss, particularly for older patients juggling multiple specialists. The review is funded through Medicare and delivered through an accredited pharmacist who visits the home, and the result is frequently a streamlined regimen that improves adherence and reduces adverse events. These services are the connective tissue between dispensing and public health.

Controlled substances, harm reduction, and the pharmacist's ethical tightrope

Few areas test the boundary between pharmacy and public health as sharply as controlled substances. During the COVID-19 pandemic, pharmacists in Australia had to balance continuity of pain management and opioid agonist therapy with the risk of overuse and diversion. The operational lessons from that period have been widely discussed, including in this reflection on managing controlled substance prescriptions during a public health emergency, which sets out practical considerations for pharmacists working at the coalface.

Harm reduction has become a defining feature of modern Australian pharmacy practice. The take-home naloxone program, which allows pharmacists to supply naloxone without a prescription in every state and territory, has been one of the most visible collaborations between community pharmacy and public health agencies responding to opioid-related harms. Pharmacists now routinely counsel patients and carers on recognising overdose, administering naloxone, and calling an ambulance, and that conversation is treated as a routine part of dispensing, not a special event.

Opioid agonist therapy presents a different challenge. The shift toward pharmacy-based dosing of methadone and buprenorphine has made treatment more accessible, particularly in regional centres like Townsville, Ballarat, and Bunbury, but it has also asked pharmacists to manage complex psychosocial presentations alongside the dispensing. Training programs delivered by the Pharmaceutical Society of Australia and the Australasian Professional Society on Alcohol and other Drugs have tried to equip pharmacists for this work. Success depends on close working relationships with prescribers, local drug and alcohol services, and Aboriginal community controlled health organisations where culturally safe care is the priority.

Mental health, suicide prevention, and the pharmacy door

Mental health is now a core strand of pharmacy practice in Australia, and it is hard to overstate how often the pharmacy counter is the place where someone first says they are not coping. The expansion of mental health first aid training for pharmacists, delivered through organisations like Mental Health First Aid Australia, has equipped more frontline staff to respond confidently when a regular customer mentions feeling overwhelmed, sleeping poorly, or having thoughts of self-harm.

Knowing when to stay quiet is itself a clinical skill, and there is more in common between a pharmacist's pause at the counter and the deliberate use of silence than many practitioners realise. Pharmacy-based screening tools for depression and anxiety, including the Patient Health Questionnaire and the Generalised Anxiety Disorder scale, are being used more widely in everyday consultations. When a pharmacist picks up an elevated score, the referral pathway now often includes a GP, a headspace centre for younger patients, or a local psychologist under a Mental Health Treatment Plan. In rural communities where headspace centres are few, pharmacists are sometimes the only clinician a young person sees in a given month, which makes that referral conversation a high-stakes moment.

Suicide prevention is where collaborative models have to be most carefully designed. Pharmacy staff in places like the Kimberley, the Pilbara, and the far north of Queensland have been involved in postvention work, supporting families after a suicide and connecting them with local services. Lifeline, Beyond Blue, and locally developed resources such as the Way Back Support Service all depend on a network that includes pharmacists, particularly in the days immediately after a discharge from hospital. The pharmacist's role is not to provide therapy, but to notice, to ask directly, and to make sure the next hand on the rope is ready.

Aboriginal and Torres Strait Islander health: working through community controlled models

Closing the gap on health outcomes for Aboriginal and Torres Strait Islander peoples is the unfinished business of Australian public health, and it cannot be done without pharmacy being part of the conversation. The National Aboriginal Community Controlled Health Organisation and its member services have led this work, and pharmacists who work alongside ACCHOs describe the experience as fundamentally different from mainstream community pharmacy. Care is team-based, culturally informed, and shaped by community priorities rather than by a script count at the end of the day.

Programs like the Aboriginal Health Worker and pharmacist partnerships in the Northern Territory and Western Australia have shown what a genuinely collaborative model looks like. Pharmacists undertake cultural safety training, often through organisations like the Congress of Aboriginal and Torres Strait Islander Nurses and Midwives or Indigenous Allied Health Australia, and they learn to work at a pace that respects community protocols. The result is better medication management for chronic conditions like diabetes and renal disease, and stronger trust in the health system overall.

The Section 100 arrangements under the Remote Area Aboriginal Health Service Program deserve a mention here as well. They allow pharmacists to supply medications directly through ACCHOs in remote communities, often in places where there is no nearby pharmacy at all. The model is built on collaboration between pharmacists, Aboriginal health practitioners, and remote area nurses, and it is one of the clearest examples in Australia of pharmacy and public health working as a single system rather than as parallel services.

Data, digital health, and the next chapter of collaboration

Digital infrastructure is the next frontier for collaborative pharmacy-public health work, and Australia is in the middle of a significant rollout. My Health Record, the Active Script List, and real-time prescription monitoring through SafeScript in Victoria and the equivalent systems in other states are all reshaping how pharmacists share information with prescribers and public health agencies. Each of these tools has the potential to reduce medication misadventure at a population level, not just for individual patients.

The opportunity is to use that infrastructure for proactive public health, not just defensive prescribing. Linked data could flag communities where anticoagulant prescribing is out of step with local atrial fibrillation rates, or where antidepressant initiation in adolescents is rising faster than expected. Pharmacists, with their access to dispensing data and their relationships with patients, are well placed to interpret those signals and act on them alongside primary health networks and local councils.

None of this will happen without sustained investment in the pharmacy workforce and a willingness to let scope of practice keep evolving. The seventh Community Pharmacy Agreement, the upcoming review of pharmacy remuneration, and the long-term workforce plan being developed by the Department of Health and Aged Care will all shape whether collaboration deepens or stalls. Pharmacists who have seen what is possible during the pandemic, in naloxone rollouts, and in ACCHO partnerships are unlikely to settle for less.

If you are a pharmacist working in community practice, now is the moment to ask your local primary health network what joint programs are already on the table and which ones still need a champion. Reach out to your state branch of the PSA or the Guild, volunteer for a screening pilot, or simply start a conversation with the public health unit in your region about how the next outbreak, the next overdose cluster, or the next suicide postvention effort might be handled together. The collaborative models that work in Australia are not the product of grand policy statements; they are the product of pharmacists, public health practitioners, and community members showing up to the same meetings and treating each other as colleagues. Your local knowledge is the ingredient the system cannot do without.